MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Pulmonology (Drugs, Pharmaceuticals, Biotechnology & Biosimilars)
*Architects: Pulmonology (Health IT, Devices & Technology)
Resmed Inc (NYSE RMD)*
Organization & Developments: ResMed
Parents
Resmed Inc (NYSE RMD)*
Children
*Developer, manufacturer & marketer of products for the screening, treatment and management of sleep-disordered breathing (SDB) &
*ResMed is a global leader in the development, manufacturing and marketing of medical products for the diagnosis, treatment and management of respiratory disorders
*ResMed operates in over 68 countries via 18 direct offices and a network of distributors
*ResMed strategic investment
*The Company Has Grown To operate in 100 countries with manufacturing sites in Australia, France, Singapore and the U.S.,
2019: ResMed-Propeller Deal: What You Need to Know
2020: ResMed to get biggest bang out of HHS ventilator contracts, analysts predict
2020: ResMed's Double-Digit Operating Leverage Is Offset By Valuation Risk
2022: ResMed Inc. 2023 Q1 - Results - Earnings Call Presentation_seekingalpha.com
2022: ResMed: Strong Earnings Growth Supports The High Valuation, Unclear Technical Trends_ seekingalpha.com
2023: As ResMed tops $1B revenues in Q2, CEO says Philips' return to the CPAP market is 'not a big perturbation' to long-term strategy
2024: A First Look At ResMed_seekingalpha.com
2024: ResMed Inc. 2024 Q2 - Results - Earnings Call Presentation_ seekingalpha.com
2024: ResMed: Asymmetrical Value Opportunity With High Prospect Of Re-Rating_ seekingalpha
2024: ResMed: Not A Sleeper_seekingalpha.com
2024: ResMed: Solid Execution, Pricey Valuation
2024: Why ResMed Is One Of My Top Picks In 2024_ seekingalpha.com
2024: Why ResMed's Rally Is Just Getting Started
2025: ResMed launches at-home sleep apnea test
Jumps
*Key People: Resmed
Finance & Acquisition: Resmed